NCT03407508

Brief Summary

There is a significant and growing interest in nutrition and health in the general population and there is also, paradoxically, an increasing problem with obesity and general debilitating conditions of affluence, such as type 2 diabetes mellitus. Igelösa Life Science AB has developed a modified Okinawan-based Nordic Diet (OBND) diet based on evidence primarily from the diet of the long-lived and healthy Okinawa population. The diet includes fish and whole grains, with a high level of vegetables, but is low in fat. In 2016, a clinical nutrition study was carried out at Kristianstad University with the intention to determine if the OBND resulted in reductions/changes in clinical and medical markers of importance for treatment of diabetes mellitus and gingivitis/periodontitis. The diet had a positive impact on the clinical progress of otherwise debilitating conditions such as diabetes and the health benefits on clinical parameters was extremely rapid, that is, within two weeks. Not only did the patients with type 2 diabetes receive the OBND, their partners were also offered the same option. This is a key innovation and the participants stated that it was a great support, which facilitated adherence and promotes the long-term impact on health. Ingrained habits such as poor diet, can only be defeated by a concerted team effort and our work to date provides a glimpse of the potential benefits to Sweden and the rest of the developed world through this shared approach. Initial studies have shown promising effects of the OBND on both diabetes and periodontal conditions. The objective of this study is to compare the OBND to the current recommended standard diet. Assuming the study provides positive evidence of health impact due to improved food quality, it will also be seen that the production and delivery of such 'healthy-living' meals will be of commercial interest for industry. The mission is to offer an evidence-based natural food alternative that both prevents disease and improves the health status of individuals with diabetes. The long-term goal is to design efficient and effective products that will protect against diabetes and other chronic diseases. The combination of scientific credibility and commercial interests may be a key factor to transfer the new knowledge about healthy dieting into actual improvements in public health.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P75+ for phase_1 diabetes-mellitus

Timeline
Completed

Started Oct 2018

Typical duration for phase_1 diabetes-mellitus

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 3, 2018

Completed
20 days until next milestone

First Posted

Study publicly available on registry

January 23, 2018

Completed
9 months until next milestone

Study Start

First participant enrolled

October 17, 2018

Completed
15 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2018

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

September 26, 2018

Status Verified

September 1, 2018

Enrollment Period

15 days

First QC Date

January 3, 2018

Last Update Submit

September 25, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • HbA1c

    Changes in levels of HbA1c (mmol/mol) in serum before and after study procedures

    Baseline, 2, 4, and 26 weeks

Secondary Outcomes (2)

  • Pro-inflammatory cytokines

    Baseline, 2, 4, and 26 weeks

  • Gingivitis

    Baseline, 2, 4, and 26 weeks

Study Arms (2)

Baseline

PLACEBO COMPARATOR

No dietary changes.

Dietary Supplement: Comparison of Diets

Comparison of Diets

PLACEBO COMPARATOR

Okinawan-based Nordic Diet or Control Diet.

Dietary Supplement: Comparison of Diets

Interventions

Comparison of DietsDIETARY_SUPPLEMENT

Okinawan-based Nordic Diet and Control Diet

BaselineComparison of Diets

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • minimum 20 teeth
  • HbA1c = 60-80 mmol/mol (diabetics), HbA1c \< 42 mmol/mol (control)
  • be able to receive food delivery monday, wednesday, friday
  • Scandinavian background

You may not qualify if:

  • use of tobacco products
  • pregnancy
  • lactose, celiac- or garlic intolerance
  • blood pressure ≥ 180 mm Hg
  • have visited dental clinic within one month Before study start or currently are undergoing dental/dental hygienist treatment
  • have rheumatoid arthritis
  • for Medical reasons need treatment with antibiotics or who has been treated with antiobiotics within one month before study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Kristianstad

Kristianstad, Skåne County, 29188, Sweden

Location

MeSH Terms

Conditions

Diabetes MellitusGingivitis

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesInfectionsGingival DiseasesPeriodontal DiseasesMouth DiseasesStomatognathic Diseases

Central Study Contacts

Cecilia Widén, PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 3, 2018

First Posted

January 23, 2018

Study Start

October 17, 2018

Primary Completion

November 1, 2018

Study Completion

December 1, 2019

Last Updated

September 26, 2018

Record last verified: 2018-09

Locations